cbdMD (YCBD) Share-based Compensation (2017 - 2025)
cbdMD (YCBD) posted Share-based Compensation of $2505.0 for Q4 2025, down 99.85% sequentially from $1.6 million in Q3 2025, and down 96.95% YoY from $82250.0 in Q4 2024.
cbdMD (YCBD) Share-based Compensation (2017 - 2025) Analysis & Trends
cbdMD has reported Share-based Compensation for 9 years, with the latest figure at $2505.0 in Q4 2025.
- Quarterly Share-based Compensation fell 96.95% year-over-year to $2505.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (up 2619.53% YoY) and the FY2025 annual result came in at $1.7 million, up 4132.15% from the prior year.
- Share-based Compensation eased to $2505.0 in Q4 2025 per YCBD's latest filing, from $1.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.7 million in Q2 2025 and troughed at -$709803.0 in Q3 2021.
- A 5-year average of $298988.9 and a median of $52767.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2025: Share-based Compensation sank 115.65% in 2021, then soared 4146.34% in 2025.
- Over 5 years, Share-based Compensation stood at $508754.0 in 2021, then sank by 91.46% to $43449.0 in 2022, then slumped by 341.9% to -$105101.0 in 2023, then soared by 178.26% to $82250.0 in 2024, then slumped by 96.95% to $2505.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2505.0, $1.6 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,505.00 |
| Dec 31, 2025 | 2,505.00 |
| Sep 30, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Mar 31, 2025 | -79,382.00 |
| Mar 31, 2025 | -79,382.00 |
| Dec 31, 2024 | 82,250.00 |
| Dec 31, 2024 | 82,250.00 |
| Sep 30, 2024 | 38,652.00 |
| Sep 30, 2024 | 38,652.00 |
| Sep 30, 2023 | -105,101.00 |
| Sep 30, 2023 | -105,101.00 |
| Jun 30, 2023 | 8,885.00 |
| Jun 30, 2023 | 8,885.00 |
| Mar 31, 2023 | 52,767.00 |
| Mar 31, 2023 | 52,767.00 |
| Dec 31, 2022 | 43,449.00 |
| Dec 31, 2022 | 43,449.00 |